0.33% ropivacaine 250ml — Competitive Intelligence Brief

0.33% ropivacaine 250ml (0.33% ropivacaine 250ml) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Cardiovascular.

marketed Local anesthetic Voltage-gated sodium channels Cardiovascular Small molecule

Target snapshot

0.33% ropivacaine 250ml (0.33% ropivacaine 250ml) — Guangzhou General Hospital of Guangzhou Military Command. Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
0.33% ropivacaine 250ml TARGET	0.33% ropivacaine 250ml	Guangzhou General Hospital of Guangzhou Military Command	marketed	Local anesthetic	Voltage-gated sodium channels
IV Lidocaine	IV Lidocaine	University of Washington	marketed	Local anesthetic / Antiarrhythmic agent (Class IB)	Voltage-gated sodium channels
Paracetamol +caudal ropivacaine	Paracetamol +caudal ropivacaine	Aga Khan University	marketed	Analgesic combination (systemic + local anesthetic)	COX inhibition (paracetamol); voltage-gated sodium channels (ropivacaine)
Lidocaine / propofol admixture	Lidocaine / propofol admixture	Benaroya Research Institute	marketed	Local anesthetic / sedative combination	Voltage-gated sodium channels (lidocaine); GABA-A receptor (propofol)
Hyperbaric bupivacaine+Sufentanil	Hyperbaric bupivacaine+Sufentanil	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)
Isobaric bupivacaine 0.5%	Isobaric bupivacaine 0.5%	Hospital Clínico Universitario de Valencia	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Lidocaine + Prilocaine	Lidocaine + Prilocaine	Galeno Desenvolvimento de Pesquisas Clínicas	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class